Table 1 The mechanism of new reagents
Disease | Reagent | Mechanism |
|---|---|---|
Tumor Metastasis and Thrombosis | NZ-12 [55] | Human-mouse chimeric antibody treating brain cancer and lung cancer. |
ChLpMab-23 [56] | Human-mouse chimeric antibody showed high sensitivity to glioblastoma and oral cancer. | |
ChLpMab-2 [57] | Human-mouse chimeric antibody showed high sensitivity to glioblastoma, mesothelioma, and lung cancer. | |
LpMab-21 [58] | High ADCC and CDC activity against ovarian cancer, glioblastoma, and lung cancer. | |
LpMab-23 [59] | Anti-PDPN to treat oral cancer. | |
NZ-27, P1027 [60] | High CDC activity against glioblastoma. | |
P2-0, MS-1, MS-3, and MS-4 [61] | Inhibitors of the binding of PDPN and CLEC-2 suppressed the growth of the tumor. | |
PG4D2, AP201 [62] | Against the interaction of PDPN and CLEC-2, both of which had inhibitory effects on the growth and metastasis of osteosarcoma. | |
LpMab-7 [63] | Diagnostic tool to identify patients with PDPN-positive osteosarcoma. | |
2A2B10 [64] | Inhibition of hematogenous metastasis and thrombosis of PDPN-positive melanoma without a significant bleeding tendency. | |
2CP [65] | Anticancer metastatic activity in vivo. | |
Co-HP [67] | The binding of Co-HP to CLEC-2 blocked the interaction between CLEC-2 and PDPN. | |
Fucoidan [68] | Restrained the progression of gastric cancer by up-regulating the level of CLEC-2. | |
AAWAP [69] | Irreversibly blocked the effects of PDPN and CLEC-2 in tumors. | |
Bisdemethocycurcumin and demethoxycurcumin [70] | Natural antagonists of CLEC-2 with anti-colon cancer activity. | |
Atherosclerosis | Ibrutinib [71] | Btk is located in the downstream of Syk, blocking CLEC-2-mediated platelet activation and tyrosine phosphorylation. |
MK-1026 [73] | ||
TRPM7 kinase [74] | The deletion of TRPM7 inhibited hemITAM-PLCγ2-mediated intracellular Ca2+ mobilization. | |
Wound Healing | Dasatinib [76] | Inhibited the downstream signaling molecules Src and Syk of CLEC-2 and blocked CLEC-2-mediated platelet activation. |